Actinogen is developing a revolutionary oral therapeutic, Xanamem®, which controls levels of the “stress hormone” cortisol in the brain, with the goal of improving the lives of patients and their families. Topline results from our first pivotal Alzheimer’s trial, evaluating its potential to slow disease progression, are expected in November 2026.

ACW XanaMIA Alzheimers open label trial commences

ACW has announced the commencement of the open‑label extension phase of the XanaMIA AD trial, with the treatment of the first eligible participant in Australia. The OLE enables all current and former participants who have completed the randomized trial to receive active Xanamem 10 mg once daily for up to 25 months, with no placebo control group.

ACW successfully completes $16.8m Placement and SPP

Actinogen is pleased to announce that its share purchase plan (SPP) is now complete, with $4.8 million raised from existing shareholders.

This brings total funding from this capital raising round to $16.8 million, when combined with
the $12.0 million in placement funding (Placement) announced on 2 February 2026.

ACW HY26 financial results - XanaMIA pivotal AD trial progress & funding secured beyond XanaMIA topline final trial results in Nov 2026

Actinogen has released its financial results for the half year ended 31 December 2025.

Highlights include progress on the XanaMIA phase 2b/3 Alzheimer’s trial, ongoing commercial readiness preparations and post half-year cash receipts that have secured funding beyond the XanaMIA topline final results in November 2026.

View the Appendix 4D and Interim Financial Report 2026 here.

ACW receives further $1.9m FY2025 R&D rebate from the ATO

Actinogen has received a further research and development tax incentive (RDTI) rebate of almost $1.9m from the ATO. This further rebate relates to overseas R&D expenditure incurred in FY2025 that remained subject to receipt of an Advanced Overseas Finding approval at the time of lodging the Company’s tax return.
When combined with the initial RDTI rebate of ~$5.5m received in October 2025, the total RDTI rebate received by ACW for the FY2025 year is $7.4m.

ACW secures funding beyond XanaMIA AD trial final results

Actinogen secures funding beyond the XanaMIA Alzheimer’s disease trial topline final results in November following the recent positive interim analysis outcome. A share placement and share purchase plan have been announced to raise up to approximately $17.0 million.

ACW December 2025 quarterly activity report & Appendix 4C

Actinogen has released its quarterly activity report and Appendix 4C f or the three-month period ended 31 December 2025.

ACW positive XanaMIA AD trial Interim Analysis outcome

The XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has recommended that the trial continue without amendment after its interim analysis. In doing so, the DMC determined that the unblinded safety and efficacy data it reviewed support continuing the trial to its completion later in the year